Atlas Trials

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Clinical trial NCT06834789 · COMPLETED

Trial details

NCT number
NCT06834789
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Glabellar Lines
Start date
2025-02-18
Primary completion
2025-11-03
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.